Impairment of bone health in pediatric patients with hemolytic anemia

Area of Science:

• Pediatric Endocrinology
• Hematology
• Bone Metabolism

Background:

• Chronic hemolytic anemias, including sickle cell anemia and thalassemia, are linked to compromised bone health in children and adults.
• Pediatric patients with various chronic hemolytic anemias may exhibit impaired bone development and health.

Purpose of the Study:

• To evaluate bone health status in pediatric patients diagnosed with chronic hemolytic anemia.
• To identify specific bone health parameters affected in this patient population.

Main Methods:

• A cross-sectional study involving 45 pediatric patients with diverse hemolytic anemias (17 sickle cell disease, 14 hereditary spherocytosis).
• Assessment included biochemical markers (e.g., 25 OH-vitamin D, RANKL, osteoprotegerin, osteocalcin), radiographic data, and patient history.
• Statistical analysis, including multiple stepwise regression, was used to determine influencing factors on bone health markers.

Main Results:

• A high prevalence of vitamin D deficiency (80.5%) was observed, with serum 25 OH-vitamin D levels below 20 ng/ml.
• Elevated RANKL/osteoprotegerin (OPG) ratios (0.26 vs. 0.08 in controls) and lower osteocalcin levels (68.5 vs. 118.0 ng/ml in controls) indicate altered bone modeling.
• Bone pain was reported in 31% of patients. Lactate dehydrogenase (LDH), diagnosis, and age significantly influenced osteocalcin levels.
• Patients with sickle cell anemia experienced more severe bone health impairment compared to those with hereditary spherocytosis.

Conclusions:

• Pediatric patients with chronic hemolytic anemia exhibit significantly impaired bone health.
• Vitamin D deficiency, an imbalanced RANKL/OPG system, and low osteocalcin levels are key contributors to bone impairment in these children.
• These findings highlight the need for monitoring and intervention strategies for bone health in pediatric hemolytic anemia patients.